(AOF) – Pharnext announces a fundraising of one million euros through the issuance of Oceane-BSA, with a nominal value of 1 million euros, subscribed by Global Tech Opportunities 13. Biotech developing new therapies for neurodegenerative diseases without a satisfactory therapeutic solution specifies that the operation gives rise to the issue of 18,552,875 BSA and could give rise to the creation of 268,552,875 new shares based on the last listed price. The participation of a shareholder holding 1% of the capital prior to this new drawing would be 0.48%.
Before the drawdown announced today, the Oceane-BSA issue raised 32.1 million euros, gave rise to the creation of 26,067,630,426 new shares and could still give rise to the creation of 91 893,773 new shares based on the last quoted price. The participation of a shareholder holding 1% of the capital prior to these drawdowns is now less than 0.001%.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.